Related Experiment Videos
IL-12 regulates VEGF and MMPs in a murine breast cancer model
1Biological Therapies Laboratory, Imperial Cancer Research Fund, London, UK. diassjr@icrf.icnet.uk
Abstract:
In a murine model of breast cancer, IL-12 therapy exerts potent anti-angiogenic effects which contribute to tumor regression. After 7 days of treatment, levels of tumor VEGF protein decline markedly and are undetectable at 14 days. This decline is accompanied by a fall in MMP-9 and, as the tumors regress, an increase in its natural inhibitor, TIMP-1. A cell line established from the primary tumor produced VEGF in vitro. IFN-gamma reduced tumor cell production of VEGF over a 24-hr period in vitro, suggesting that IL-12-induced IFN-gamma may be responsible for the decline in VEGF levels in vivo. There is also in vitro evidence that IL-12 regulates stromal cell interactions, leading to decreased MMP-9 and increased TIMP-1 production. Thus, we suggest that at least 2 mechanisms are involved in IL-12 regulation of angiogenesis, removing the pro-angiogenic stimulus and blocking the release and activity of MMPs.
Insights
Interleukin-12 (IL-12) therapy effectively inhibits breast cancer growth by reducing tumor angiogenesis. This therapy decreases vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9), promoting tumor regression.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Angiogenesis is crucial for tumor growth and metastasis.
- Interleukin-12 (IL-12) is a cytokine with known immunomodulatory and anti-tumor properties.
- Understanding the mechanisms of IL-12's anti-angiogenic effects is critical for cancer therapy development.
Purpose of the Study:
- To investigate the anti-angiogenic mechanisms of IL-12 therapy in a murine breast cancer model.
- To determine the effects of IL-12 on key angiogenic factors like VEGF, MMP-9, and TIMP-1.
- To elucidate the role of IFN-gamma and stromal cell interactions in IL-12-mediated anti-angiogenesis.
Main Methods:
- Establishment of a murine model of breast cancer.
- Administration of IL-12 therapy and monitoring of tumor growth.
- Quantification of tumor VEGF, MMP-9, and TIMP-1 levels at different time points.
- In vitro studies using a breast cancer cell line to assess VEGF production and the effects of IFN-gamma.
- In vitro studies to evaluate IL-12's impact on stromal cell interactions.
Main Results:
- IL-12 therapy significantly reduced tumor vascular endothelial growth factor (VEGF) levels, with undetectable levels by day 14.
- A decrease in matrix metalloproteinase-9 (MMP-9) and an increase in its inhibitor, TIMP-1, were observed during tumor regression.
- In vitro, IFN-gamma (induced by IL-12) reduced VEGF production by tumor cells.
- In vitro, IL-12 modulated stromal cell interactions, decreasing MMP-9 and increasing TIMP-1 production.
Conclusions:
- IL-12 therapy exerts potent anti-angiogenic effects in breast cancer by reducing tumor VEGF levels, likely mediated by IFN-gamma.
- IL-12 also inhibits angiogenesis by altering stromal cell interactions, leading to decreased MMP-9 and increased TIMP-1.
- These dual mechanisms, targeting both pro-angiogenic stimuli and MMP activity, contribute to IL-12's tumor regression effects.